ImmunoCellular Therapeutics To Report Financial Results For The Third Quarter, 2013 On November 6th

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that it plans to report third quarter, 2013 financial results on Wednesday, November 6, 2013. ImmunoCellular will host a conference call and webcast to discuss financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President and CEO.
       
LIVE CALL: (877) 853-5636 (toll-free)
Conference code: 88446644
 
REPLAY: (855) 859-2056 (toll-free)
(404) 537-3406
Conference code: 88446644
(Replay available from Wednesday, November 6, 2013 at 8:00 pm until Wednesday, November 13, 2013 at 11:59 pm.)
 

The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of ImmunoCellular's website at www.imuc.com. The information provided on the teleconference is accurate only at the time of the conference call, and ImmunoCellular will take no responsibility for providing updated information except as required by law.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular’s pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.

Copyright Business Wire 2010

If you liked this article you might like

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

5 Stocks Poised for Breakouts

4 Stocks Under $10 to Trade for Breakouts